Distinctive clinicopathological features and KRAS and IDH1/2 mutation status of cholangiolocellular carcinoma.
IDH mutation
cholangiolocellular carcinoma
combined hepatocellular cholangiocarcinoma
intermediate cell carcinoma
intrahepatic cholangiocarcinoma
primary liver cancer
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
28
05
2019
revised:
05
09
2019
accepted:
15
09
2019
pubmed:
17
11
2019
medline:
17
11
2019
entrez:
17
11
2019
Statut:
ppublish
Résumé
Cholangiolocellular carcinoma (CLC) is classified as a subtype of combined hepatocellular cholangiocarcinoma with stem-cell features (CHC-SC) in the latest World Health Organization classification. This subclassification of CHC-SCs is controversial and the relevance of such classification is unclear. We analyzed a series of CHC-SCs and intrahepatic cholangiocarcinoma (iCCA) to clarify the clinicopathological features and mutational status of each tumor. Background liver disease, fibrosis stage, microvascular invasion, nodal metastasis, and IDH1/2 mutation status were associated with their histology. Compared with the intermediate cell subtype of CHC-SC (CHCs-SC-int), CLCs were less frequently associated with chronic viral hepatitis, and showed lower levels of serum alpha-fetoprotein. Compared with iCCAs, CLCs showed lower levels of serum carbohydrate antigen 19-9 (CA19-9) and a lower frequency of expression of S100P. Patients with iCCA showed worse overall survival than those with CLC or CHC-SC-int. In patients with iCCA, CLC, or CHC-SC-int, a histology of iCCA, microvascular invasion, and serum CA19-9 value of >100 U/mL were significant poor prognostic factors for overall survival in univariate analysis. Multivariate analysis showed that a high serum CA19-9 value was an independent poor prognostic factor for overall survival. Patients with CLC are likely to have a different etiology and mutational background from those with CHC-SC-int. Their clinicopathological manifestations are also different from those with classic iCCA. Our results suggest that CLC might be a distinct entity among primary liver carcinomas.
Types de publication
Journal Article
Langues
eng
Pagination
84-91Subventions
Organisme : JSPS KAKENHI
ID : 16K19096
Informations de copyright
© 2019 The Japan Society of Hepatology.
Références
Steiner PE, Higginson J. Cholangiolocellular carcinoma of the liver. Cancer 1959; 12: 753-759.
Theise ND, Nakashima O, Park YN et al. Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban R, Theise ND, eds. WHO Classification of Tumours of the Digestive System, 4th edn. 3: Lyon, FranceInternational Agency for Research on Cancer, 2010; 225-227.
Komuta M, Spee B, Vander Borght S et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-1556.
Zhang L, Theise N, Chua M et al. The stem cell niche of human livers: Symmetry between development and regeneration. Hepatology 2008; 48: 1598-1607.
Yu TH, Yuan RH, Chen YL et al. Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression. Mod Pathol 2011; 24: 810-819.
Kondo F, Fukusato T. Pathogenesis of cholangiolocellular carcinoma: Possibility of an interlobular duct origin. Intern Med 2015; 54: 1685-1694.
Roskams TA, Theise ND, Balabaud C et al. Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39: 1739-1745.
Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
Borger DR, Tanabe KK, Fan KC et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17: 72-79.
Saha SK, Parachoniak CA, Ghanta KS et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 2014; 513: 110-114.
Liau JY, Tsai JH, Yuan RH et al. Morphological subclassification of intrahepatic cholangiocarcinoma: Etiological, clinicopathological, and molecular features. Mod Pathol 2014; 27: 1163-1173.
Hayashi A, Misumi K, Shibahara J et al. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol 2016; 40: 1021-1030.
Brunt E, Aishima S, Clavien PA et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology 2018; 68: 113-126.
Tanaka H, Tsuji M. From discovery to eradication of schistosomiasis in Japan: 1847-1996. Int J Parasitol 1997; 27: 1465-1480.
Chen J, He J, Deng M et al. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. Hum Pathol 2017; 64: 118-127.
Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology 2017; 70: 423-434.
Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 2016; 27: 599-608.
Chen Y, Wong PP, Sjeklocha L et al. Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. Hepatology 2012; 55: 563-574.
Tarlow BD, Pelz C, Naugler WE et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 2014; 15: 605-618.
Kawai-Kitahata F, Asahina Y, Kaneko S et al. Comprehensive genetic analysis of cholangiolocellular carcinoma with a coexistent hepatocellular carcinoma-like area and metachronous hepatocellular carcinoma. Hepatol Res 2019; [Epub ahead of print].
Sugiura T, Uesaka K, Kanemoto H et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012; 16: 977-985.
Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol 2005; 166: 81-92.
Aishima S, Fujita N, Mano Y et al. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: Carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol 2011; 35: 590-598.
Moeini A, Sia D, Zhang Z et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017; 66: 952-961.
Sia D, Villanueva A, Friedman SL et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 2017; 152: 745-761.
Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev 2018; 4: CD011746.
Fujii T, Khawaja MR, DiNardo CD et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med 2016; 21: 373-380.